We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Arl3.0
Argireline Research
Mostly mechanism / observationalHigh safety
6 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Argireline studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2002–2017.
Based on 6 studies · 3 RCTs
Confidence
Moderate
By outcome
Skin health
Mostly mechanism / observational3 studies
Safety profile
Too few graded studies1 study
Older research base
Newest study from 2017
200220092017
1RCT2013
In the objective evaluation, the parameters of roughness were all decreased in the argireline group (p < 0.01), while no decrease was obvious in the placebo group (p > 0.05).
Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. · Am J Clin Dermatol (2013)
Randomized, placebo-controlled topical trial: 60 subjects (3:1 Argireline:placebo) applied product to peri-orbital wrinkles twice daily for 4 weeks
Objective silicone-replica wrinkle analysis showed all roughness parameters decreased significantly in the Argireline group (p < 0.01) and not in placebo
Subjective total anti-wrinkle efficacy was 48.9% with Argireline vs 0% with placebo
Double-blind, placebo-controlled, randomized trial of daily topical application of AH8 in 24 patients with BSP... There were no significant adverse events.
Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. · Eur J Neurol (2013)
NIH double-blind, placebo-controlled, randomized pilot of topical acetyl hexapeptide-8 (a competitive SNAP-25 inhibitor) in 24 blepharospasm patients
No significant adverse events — supports topical safety
Only a non-significant trend toward longer time to return to baseline after botulinum-toxin injection in the active group (3.7 vs 3.0 months)
skin topography analysis of an oil/water (O/W) emulsion containing 10% of the hexapeptide on healthy women volunteers reduced wrinkle depth up to 30% upon 30 days treatment.
Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. · Int J Cosmet Sci (2002)
Foundational design paper: the hexapeptide Ac-EEMQRR-NH2 ('Argireline') was rationally designed to mimic the cosmetic action of botulinum toxin non-toxically
A 10% O/W emulsion reduced wrinkle depth up to ~30% over 30 days in a small, uncontrolled cohort of healthy women — an appearance measure, not a controlled trial
Mechanistically, the peptide inhibited neurotransmitter release with potency similar to BoNT-A but much lower efficacy, by interfering with SNARE-complex formation/stability
Our results confirm the antiwrinkle activity of acetyl hexapeptide-3. A significant decrease in TEWL with acetyl hexapeptide-3 treatment is observed.
Raikou V, Varvaresou A, Panderi I, Papageorgiou E. · J Cosmet Dermatol (2017)
Prospective, randomized controlled cosmetic-science study in 24 volunteers comparing acetyl hexapeptide-3, tripeptide-10-citrulline, their combination, and neither, over 60 days
the significant cytotoxicity of argireline solution was observed under 18 to 10 000 fold higher concentrations (depending on cells that were examined) in comparison to doxorubicin.
Grosicki M, Latacz G, Szopa A, Cukier A, Kieć-Kononowicz K. · Acta Biochim Pol (2014)
Independent in-vitro cytotoxicity study across HEK-293, IMR-32 neuroblastoma, and human primary skin fibroblasts
Anti-proliferative effects were dose-dependent but appeared only at 18- to 10,000-fold higher concentrations than the reference cytotoxin doxorubicin
Supports a wide topical safety margin for cosmetic-use concentrations
6Review2007
This article reviews the physiological basis and mechanism of action of the active cosmetic ingredient acetyl hexapeptide-8 (Argireline).